Target regimen profiles for tuberculosis treatment

Christian Lienhardt; Kelly E Dooley; Payam Nahid; Charles Wells; Theresa S Ryckman; Emily A Kendall; Gerry Davies; Grania Brigden; Gavin Churchyard; Daniela Maria Cirillo; Eugenia Di Meco; Ramya Gopinath; Carole Mitnick; Cherise Scott; Farhana Amanullah; Cathy Bansbach; Martin Boeree; Michael Campbell; Francesca Conradie; Angela Crook; Charles L Daley; Keertan Dheda; Andreas Diacon; Agnes Gebhard; Debra Hanna; Norbert Heinrich; Anneke Hesseling; David Holtzman; Mathilde Jachym; Peter Kim; Christoph Lange; Lindsay McKenna; Graeme Meintjes; Norbert Ndjeka; Nguyen Viet Nhung; Bern-Thomas Nyang'wa; Nicholas I Paton; Raghuram Rao; Michael Rich; Rada Savic; Ingrid Schoeman; Boitumelo Semete Makokotlela; Mel Spigelman; Eugene Sun; Elin Svensson; Phumeza Tisile; Francis Varaine; Andrew Vernon; Mukadi Ya Diul; Tereza Kasaeva; Matteo Zignol; Medea Gegia; Fuad Mirzayev; Samuel G Schumacher

doi:10.2471/BLT.24.291881

Retour

Target regimen profiles for tuberculosis treatment

Article de revue

Avec comité de lecture

Target regimen profiles for tuberculosis treatment

Christian Lienhardt, Kelly E Dooley, Payam Nahid, Charles Wells, Theresa S Ryckman, Emily A Kendall, Gerry Davies, Grania Brigden, Gavin Churchyard, Daniela Maria Cirillo, …

Bulletin of the World Health Organization, Vol.102(8), pp.600-607

01/08/2024

DOI: https://doi.org/10.2471/BLT.24.291881

PMCID: 11276158

PMID: 39070602

Résumé

Antitubercular Agents - therapeutic use

Cost-Benefit Analysis

Humans

Medication Adherence

Rifampin - therapeutic use

Tuberculosis - drug therapy

Tuberculosis, Multidrug-Resistant - drug therapy

World Health Organization

Simpler, shorter, safer and more effective treatments for tuberculosis that are easily accessible to all people with tuberculosis are desperately needed. In 2016, the World Health Organization (WHO) developed target regimen profiles for the treatment of tuberculosis to make drug developers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles. We used a similar process as for the 2016 profiles, including a baseline treatment landscape analysis, an initial stakeholder survey, modelling studies estimating the impact and cost-effectiveness of novel tuberculosis treatment regimens, and an extensive stakeholder consultation. We developed target regimen profiles for the treatment of rifampicin-susceptible and rifampicin-resistant tuberculosis, as well as a pan-tuberculosis regimen that would be appropriate for patients with any type of tuberculosis. We describe the revised target regimen profile characteristics, with specific minimal and optimal targets to be met, rationale and justification, and aspects relevant to all target regimen profiles (drug susceptibility testing, adherence and forgiveness, treatment strategies, post-tuberculosis lung disease, and cost and access considerations). We discuss the trade-offs of proposed characteristics for decision-making at developmental or operational levels. We expect that, following these target regimen profile revisions, tuberculosis treatment developers will produce regimens that are quality-assured, affordable and widely available, and that meet the needs of affected populations.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Target regimen profiles for tuberculosis treatment
Créateurs - sans rôle: Christian Lienhardt - French National Research Institute for Sustainable Development, Montpellier, France
Kelly E Dooley - Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA)
Payam Nahid - University of California, San Francisco
Charles Wells - Bill & Melinda Gates Medical Research Institute, Boston, USA
Theresa S Ryckman - Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA
Emily A Kendall - Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA
Gerry Davies - Institute of Infection and Global Health, University of Liverpool, Liverpool, England
Grania Brigden - The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
Gavin Churchyard - Aurum Institute, Johannesburg, South Africa
Daniela Maria Cirillo - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy
Eugenia Di Meco - European Medicines Agency, Amsterdam, Kingdom of the Netherlands
Ramya Gopinath - Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA
Carole Mitnick - Harvard Medical School
Cherise Scott - Unitaid, Geneva, Switzerland
Farhana Amanullah - Indus Hospital, Karachi, Pakistan
Cathy Bansbach - ChinaCat Enterprises, Gig Harbor, USA
Martin Boeree - University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands
Michael Campbell - Clinton Health Access Initiative, Boston, USA
Francesca Conradie - Wits Health Consortium, Johannesburg, South Africa
Angela Crook - MRC Clinical Trials Unit, University College of London, London, England
Charles L Daley - Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, USA
Keertan Dheda - Centre for Lung Infection and Immunity, University of Cape Town, Cape Town, South Africa
Andreas Diacon - TASK, Cape Town, South Africa
Agnes Gebhard - KNCV, The Hague, Kingdom of the Netherlands
Debra Hanna - Global Health Division, Bill & Melinda Gates Foundation, Seattle, USA
Norbert Heinrich - Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU, Munich, Germany
Anneke Hesseling - Stellenbosch University
David Holtzman - Bill & Melinda Gates Medical Research Institute, Boston, USA
Mathilde Jachym - Centre Hospitalier de Bligny, Fontenay-lès-Briis, Paris, France
Peter Kim - Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, United States of America (USA)
Christoph Lange - Institute for Global Health, University of California San Francisco, San Francisco, USA
Lindsay McKenna - Bill & Melinda Gates Medical Research Institute, Boston, USA
Graeme Meintjes - Infectious Disease Division, School of Medicine, John Hopkins University, Baltimore, USA
Norbert Ndjeka - Institute of Infection and Global Health, University of Liverpool, Liverpool, England
Nguyen Viet Nhung - The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland
Bern-Thomas Nyang'wa - Aurum Institute, Johannesburg, South Africa
Nicholas I Paton - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, Milan, Italy
Raghuram Rao - European Medicines Agency, Amsterdam, Kingdom of the Netherlands
Michael Rich - Division of Anti-Infectives, Food and Drug Administration, WashingtonDC, USA
Rada Savic - Institute for Global Health, University of California San Francisco, San Francisco, USA
Ingrid Schoeman - School of Medicine, Harvard Medical School, Boston, USA
Boitumelo Semete Makokotlela - Unitaid, Geneva, Switzerland
Mel Spigelman - Indus Hospital, Karachi, Pakistan
Eugene Sun - Indus Hospital, Karachi, Pakistan
Elin Svensson - University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands
Phumeza Tisile - School of Medicine, Harvard Medical School, Boston, USA
Francis Varaine - ChinaCat Enterprises, Gig Harbor, USA
Andrew Vernon - University Medical Center, Radboud University, Amsterdam, Kingdom of the Netherlands
Mukadi Ya Diul - Clinton Health Access Initiative, Boston, USA
Tereza Kasaeva - Wits Health Consortium, Johannesburg, South Africa
Matteo Zignol - Wits Health Consortium, Johannesburg, South Africa
Medea Gegia - Wits Health Consortium, Johannesburg, South Africa
Fuad Mirzayev - Wits Health Consortium, Johannesburg, South Africa
Samuel G Schumacher - Wits Health Consortium, Johannesburg, South Africa
Détails de publication: Bulletin of the World Health Organization, Vol.102(8), pp.600-607
Identifiants: 99158526709311
Unité académique: Recherches translationnelles sur le VIH et les Maladies Infect. Endém. émerg. - TransVIHMI
Langue: English
Type de ressource: Journal article